NCCN  ||| S:0 E:5 ||| NNP
Oncology  ||| S:5 E:14 ||| NNP
Risk  ||| S:14 E:19 ||| NNP
Evaluation  ||| S:19 E:30 ||| NNP
and  ||| S:30 E:34 ||| CC
Mitigation  ||| S:34 E:45 ||| NNP
Strategies  ||| S:45 E:56 ||| NNP
White  ||| S:56 E:62 ||| NNP
Paper ||| S:62 E:67 ||| NNP
:  ||| S:67 E:69 ||| :
Recommendations  ||| S:69 E:85 ||| NNP
for  ||| S:85 E:89 ||| IN
Stakeholders  ||| S:89 E:102 ||| NNP
REMS  ||| S:102 E:107 ||| NNP
are  ||| S:107 E:111 ||| VBP
a  ||| S:111 E:113 ||| DT
particularly  ||| S:113 E:126 ||| RB
important  ||| S:126 E:136 ||| JJ
issue  ||| S:136 E:142 ||| NN
for  ||| S:142 E:146 ||| IN
oncology  ||| S:146 E:155 ||| NN
and  ||| S:155 E:159 ||| CC
the  ||| S:159 E:163 ||| DT
National  ||| S:163 E:172 ||| NNP
Comprehensive  ||| S:172 E:186 ||| NNP
Cancer  ||| S:186 E:193 ||| NNP
Network  ||| S:193 E:201 ||| NNP
( ||| S:201 E:202 ||| -LRB-
NCCN ||| S:202 E:206 ||| NNP
) ||| S:206 E:207 ||| -RRB-
.  ||| S:207 E:209 ||| .
A  ||| S:209 E:211 ||| DT
disproportionate  ||| S:211 E:228 ||| JJ
number  ||| S:228 E:235 ||| NN
of  ||| S:235 E:238 ||| IN
drugs  ||| S:238 E:244 ||| NNS
with  ||| S:244 E:249 ||| IN
complex  ||| S:249 E:257 ||| JJ
REMS  ||| S:257 E:262 ||| NNS
are  ||| S:262 E:266 ||| VBP
used  ||| S:266 E:271 ||| VBN
in  ||| S:271 E:274 ||| IN
patients  ||| S:274 E:283 ||| NNS
with  ||| S:283 E:288 ||| IN
cancer  ||| S:288 E:295 ||| NN
or  ||| S:295 E:298 ||| CC
hematologic  ||| S:298 E:310 ||| JJ
disorders ||| S:310 E:319 ||| NNS
.  ||| S:319 E:321 ||| .
REMS  ||| S:321 E:326 ||| NNP
policies  ||| S:326 E:335 ||| NNS
and  ||| S:335 E:339 ||| CC
processes  ||| S:339 E:349 ||| NNS
within  ||| S:349 E:356 ||| IN
oncology  ||| S:356 E:365 ||| NNS
may  ||| S:365 E:369 ||| MD
act  ||| S:369 E:373 ||| VB
as  ||| S:373 E:376 ||| IN
a  ||| S:376 E:378 ||| DT
model  ||| S:378 E:384 ||| NN
for  ||| S:384 E:388 ||| IN
other  ||| S:388 E:394 ||| JJ
clinical  ||| S:394 E:403 ||| JJ
areas ||| S:403 E:408 ||| NNS
.  ||| S:408 E:410 ||| .
A  ||| S:410 E:412 ||| DT
breadth  ||| S:412 E:420 ||| NN
of  ||| S:420 E:423 ||| IN
experience  ||| S:423 E:434 ||| NN
and  ||| S:434 E:438 ||| CC
access  ||| S:438 E:445 ||| NN
to  ||| S:445 E:448 ||| TO
a  ||| S:448 E:450 ||| DT
wide  ||| S:450 E:455 ||| JJ
knowledge  ||| S:455 E:465 ||| NN
base  ||| S:465 E:470 ||| NN
exists  ||| S:470 E:477 ||| VBZ
within  ||| S:477 E:484 ||| IN
oncology  ||| S:484 E:493 ||| NNS
that  ||| S:493 E:498 ||| WDT
will  ||| S:498 E:503 ||| MD
ensure  ||| S:503 E:510 ||| VB
appropriate  ||| S:510 E:522 ||| JJ
development  ||| S:522 E:534 ||| NN
and  ||| S:534 E:538 ||| CC
consideration  ||| S:538 E:552 ||| NN
of  ||| S:552 E:555 ||| IN
the  ||| S:555 E:559 ||| DT
practical  ||| S:559 E:569 ||| JJ
implications  ||| S:569 E:582 ||| NNS
of  ||| S:582 E:585 ||| IN
REMS ||| S:585 E:589 ||| NNP
.  ||| S:589 E:591 ||| .
NCCN  ||| S:591 E:596 ||| NNP
is  ||| S:596 E:599 ||| VBZ
uniquely  ||| S:599 E:608 ||| RB
positioned  ||| S:608 E:619 ||| VBN
to  ||| S:619 E:622 ||| TO
assume  ||| S:622 E:629 ||| VB
a  ||| S:629 E:631 ||| DT
leadership  ||| S:631 E:642 ||| NN
role  ||| S:642 E:647 ||| NN
in  ||| S:647 E:650 ||| IN
this  ||| S:650 E:655 ||| DT
process  ||| S:655 E:663 ||| NN
given  ||| S:663 E:669 ||| VBN
its  ||| S:669 E:673 ||| PRP$
status  ||| S:673 E:680 ||| NN
as  ||| S:680 E:683 ||| IN
the  ||| S:683 E:687 ||| DT
arbiter  ||| S:687 E:695 ||| NN
of  ||| S:695 E:698 ||| IN
high-quality  ||| S:698 E:711 ||| JJ
cancer  ||| S:711 E:718 ||| NN
care  ||| S:718 E:723 ||| NN
based  ||| S:723 E:729 ||| VBN
on  ||| S:729 E:732 ||| IN
its  ||| S:732 E:736 ||| PRP$
world-leading  ||| S:736 E:750 ||| JJ
institutions  ||| S:750 E:763 ||| NNS
and  ||| S:763 E:767 ||| CC
clinicians ||| S:767 E:777 ||| NN
.  ||| S:777 E:779 ||| .
Notwithstanding  ||| S:779 E:795 ||| IN
the  ||| S:795 E:799 ||| DT
potential  ||| S:799 E:809 ||| JJ
benefits ||| S:809 E:817 ||| NNS
,  ||| S:817 E:819 ||| ,
the  ||| S:819 E:823 ||| DT
successful  ||| S:823 E:834 ||| JJ
design ||| S:834 E:840 ||| NN
,  ||| S:840 E:842 ||| ,
implementation ||| S:842 E:856 ||| NN
,  ||| S:856 E:858 ||| ,
and  ||| S:858 E:862 ||| CC
analysis  ||| S:862 E:871 ||| NN
of  ||| S:871 E:874 ||| IN
the  ||| S:874 E:878 ||| DT
FDA ||| S:878 E:881 ||| NNP
's  ||| S:881 E:884 ||| POS
recent  ||| S:884 E:891 ||| JJ
requirement  ||| S:891 E:903 ||| NN
for  ||| S:903 E:907 ||| IN
REMS  ||| S:907 E:912 ||| NNP
for  ||| S:912 E:916 ||| IN
some  ||| S:916 E:921 ||| DT
high-risk  ||| S:921 E:931 ||| JJ
drugs  ||| S:931 E:937 ||| NNS
and  ||| S:937 E:941 ||| CC
biologics  ||| S:941 E:951 ||| NNS
will  ||| S:951 E:956 ||| MD
present  ||| S:956 E:964 ||| VB
significant  ||| S:964 E:976 ||| JJ
challenges  ||| S:976 E:987 ||| NNS
for  ||| S:987 E:991 ||| IN
stakeholders ||| S:991 E:1003 ||| NN
,  ||| S:1003 E:1005 ||| ,
including  ||| S:1005 E:1015 ||| VBG
patients ||| S:1015 E:1023 ||| NNS
,  ||| S:1023 E:1025 ||| ,
providers ||| S:1025 E:1034 ||| NNS
,  ||| S:1034 E:1036 ||| ,
cancer  ||| S:1036 E:1043 ||| NN
centers ||| S:1043 E:1050 ||| NNS
,  ||| S:1050 E:1052 ||| ,
manufacturers ||| S:1052 E:1065 ||| NNS
,  ||| S:1065 E:1067 ||| ,
payors ||| S:1067 E:1073 ||| NN
,  ||| S:1073 E:1075 ||| ,
health  ||| S:1075 E:1082 ||| NN
information  ||| S:1082 E:1094 ||| NN
technology  ||| S:1094 E:1105 ||| NN
vendors ||| S:1105 E:1112 ||| NNS
,  ||| S:1112 E:1114 ||| ,
and  ||| S:1114 E:1118 ||| CC
regulatory  ||| S:1118 E:1129 ||| JJ
agencies ||| S:1129 E:1137 ||| NNS
.  ||| S:1137 E:1139 ||| .
To  ||| S:1139 E:1142 ||| TO
provide  ||| S:1142 E:1150 ||| VB
guidance  ||| S:1150 E:1159 ||| VBN
to  ||| S:1159 E:1162 ||| TO
these  ||| S:1162 E:1168 ||| DT
stakeholders  ||| S:1168 E:1181 ||| NN
regarding  ||| S:1181 E:1191 ||| VBG
REMS  ||| S:1191 E:1196 ||| NNP
challenges ||| S:1196 E:1206 ||| NNS
,  ||| S:1206 E:1208 ||| ,
the  ||| S:1208 E:1212 ||| DT
NCCN  ||| S:1212 E:1217 ||| NNP
assembled  ||| S:1217 E:1227 ||| VBD
a  ||| S:1227 E:1229 ||| DT
work  ||| S:1229 E:1234 ||| NN
group  ||| S:1234 E:1240 ||| NN
comprised  ||| S:1240 E:1250 ||| NN
of  ||| S:1250 E:1253 ||| IN
thought  ||| S:1253 E:1261 ||| NN
leaders  ||| S:1261 E:1269 ||| NNS
from  ||| S:1269 E:1274 ||| IN
NCCN  ||| S:1274 E:1279 ||| NNP
Member  ||| S:1279 E:1286 ||| NNP
Institutions  ||| S:1286 E:1299 ||| NNPS
and  ||| S:1299 E:1303 ||| CC
other  ||| S:1303 E:1309 ||| JJ
outside  ||| S:1309 E:1317 ||| JJ
experts ||| S:1317 E:1324 ||| NNS
.  ||| S:1324 E:1326 ||| .
The  ||| S:1326 E:1330 ||| DT
Work  ||| S:1330 E:1335 ||| NNP
Group  ||| S:1335 E:1341 ||| NNP
identified  ||| S:1341 E:1352 ||| VBD
challenges  ||| S:1352 E:1363 ||| NNS
across  ||| S:1363 E:1370 ||| IN
the  ||| S:1370 E:1374 ||| DT
REMS  ||| S:1374 E:1379 ||| NNP
spectrum ||| S:1379 E:1387 ||| NN
,  ||| S:1387 E:1389 ||| ,
including  ||| S:1389 E:1399 ||| VBG
the  ||| S:1399 E:1403 ||| DT
areas  ||| S:1403 E:1409 ||| NNS
of  ||| S:1409 E:1412 ||| IN
standardization ||| S:1412 E:1427 ||| NN
,  ||| S:1427 E:1429 ||| ,
development  ||| S:1429 E:1441 ||| NN
and  ||| S:1441 E:1445 ||| CC
assessment  ||| S:1445 E:1456 ||| NN
of  ||| S:1456 E:1459 ||| IN
REMS  ||| S:1459 E:1464 ||| NNP
programs ||| S:1464 E:1472 ||| NNS
,  ||| S:1472 E:1474 ||| ,
medication  ||| S:1474 E:1485 ||| NN
guides ||| S:1485 E:1491 ||| NNS
,  ||| S:1491 E:1493 ||| ,
provider  ||| S:1493 E:1502 ||| NN
knowledge  ||| S:1502 E:1512 ||| NN
and  ||| S:1512 E:1516 ||| CC
impact  ||| S:1516 E:1523 ||| NN
on  ||| S:1523 E:1526 ||| IN
prescribing ||| S:1526 E:1537 ||| NN
,  ||| S:1537 E:1539 ||| ,
provider  ||| S:1539 E:1548 ||| NN
burden  ||| S:1548 E:1555 ||| NN
and  ||| S:1555 E:1559 ||| CC
compensation ||| S:1559 E:1571 ||| NN
,  ||| S:1571 E:1573 ||| ,
and  ||| S:1573 E:1577 ||| CC
incorporation  ||| S:1577 E:1591 ||| NN
of  ||| S:1591 E:1594 ||| IN
REMS  ||| S:1594 E:1599 ||| NNP
into  ||| S:1599 E:1604 ||| IN
clinical  ||| S:1604 E:1613 ||| JJ
practice ||| S:1613 E:1621 ||| NN
.  ||| S:1621 E:1623 ||| .
